Skip to main content
NCBI home page
PLOS Genetics logoLink to PLOS Genetics
. 2022 Sep 7;18(9):e1010388. doi: 10.1371/journal.pgen.1010388

Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children

Shaobo Li 1, Charleston W K Chiang 1,2, Swe Swe Myint 1, Katti Arroyo 1, Tsz Fung Chan 1, Libby Morimoto 3, Catherine Metayer 3, Adam J de Smith 1, Kyle M Walsh 4,*, Joseph L Wiemels 1,*
Editor: Zoltán Kutalik5
PMCID: PMC9484652  PMID: 36070312

Abstract

Background

Pilocytic astrocytoma (PA) is the most common pediatric brain tumor. PA has at least a 50% higher incidence in populations of European ancestry compared to other ancestral groups, which may be due in part to genetic differences.

Methods

We first compared the global proportions of European, African, and Amerindian ancestries in 301 PA cases and 1185 controls of self-identified Latino ethnicity from the California Biobank. We then conducted admixture mapping analysis to assess PA risk with local ancestry.

Results

We found PA cases had a significantly higher proportion of global European ancestry than controls (case median = 0.55, control median = 0.51, P value = 3.5x10-3). Admixture mapping identified 13 SNPs in the 6q14.3 region (SNX14) contributing to risk, as well as three other peaks approaching significance on chromosomes 7, 10 and 13. Downstream fine mapping in these regions revealed several SNPs potentially contributing to childhood PA risk.

Conclusions

There is a significant difference in genomic ancestry associated with Latino PA risk and several genomic loci potentially mediating this risk.

Author summary

Childhood brain tumors are among the most prevalent and lethal childhood cancers. Despite this, the epidemiology as well as genetic risks are not well defined. For example, children of European ancestry have a higher risk of contracting pilocytic astrocytoma (PA) compared to other ancestries, but the genetic or environmental basis for this is unknown. Latino children are a mixture of multiple ancestries including European, African, and Native American. Using a group of Californian Latino children, we show that the risk of PA increases when a Latino child has a higher proportion of European ancestry. This global ancestry difference shows that germline genetic risk alleles contribute to a higher PA risk in children of European descendent. Moreover, this ancestral risk is localized to specific regions of the genome, especially in Chromosome 6 near the SNX14 gene, which is associated with cancer-related growth signaling pathway described by MAPK/ERK. This result brings us one step closer to understanding the etiology of this common childhood brain tumor.

Highlights

  • Higher global European ancestry proportion in Latino population is associated with higher pilocytic astrocytoma (PA) risk.

  • Local ancestry analysis suggested variants in SNX14 could contribute to PA risk, and fine mapping results pointed to SNPs related to MAPK pathway as potential risk alleles.

Introduction

Pilocytic astrocytoma (PA) is a slow-growing, benign primary central nervous system tumor that most commonly arises in the cerebellum and chiasmatic/hypothalamic region [1]. It has a high survival rate, and most cases can be cured with resection. However, PAs are the most common pediatric brain tumor and their sensitive intracranial location–including the optic pathway–can lead to significant and lifelong morbidity. Additionally, some PAs show molecular similarities to malignant gliomas and require aggressive treatment [2].

Little is known about the molecular etiology of childhood PA. While hallmark somatic mutations have been reported to underlie PA tumorigenesis, including NF1 [3], KRAS [4], PTEN [5], and BRAF [6], heritable genetic contributions impacting risk of PA remain largely unidentified, other than in the context of Neurofibromatosis Type I, where it was shown Neurofibromatosis Type I patients have a higher chance of contracting optic pathway PA, most likely due to NF1 mutations [7].

PA incidence is significantly higher in populations of European ancestry compared to other ancestries. According to a report from The Central Brain Tumor Registry of the United States (CBTRUS) [8], the average annual age-adjusted incidence rate of pilocytic astrocytoma was 0.38 (95% CI: 0.37–0.39) per 100,000 per year in non-Hispanic whites, much higher than among U.S. Latinos, 0.24 (0.23–0.26), African-Americans, 0.26 (0.24–0.29), American Indian/Alaskan Natives, 0.14 (0.10–0.19), and Asian/Pacific Islanders, 0.13 (0.11–0.16). This variation in incidence implicates differences in the distribution of underlying risk factors, including ancestry-associated genetic risk alleles and ancestry-related environmental factors. To-date there has not been a rigorous exploration of these racial/ethnic differences in terms of genetic predisposition, either on a genome-wide background level or at specific loci. However, prior genomic analyses in admixed populations have observed increases in risk of both childhood ependymoma risk and adult glioma risk in association with genome-wide differences in ancestry. [9,10] Furthermore, these studies have implicated both novel and well-validated glioma-associated genes in contributing to racial/ethnic differences in tumor risk. Using a multi-ethnic population of California children with PA and matched controls, we therefore sought to investigate both global differences in genomic ancestry and locus-specific differences to identify genetic factors associated with development of childhood PA.

Materials and methods

Study participants

An overview of the subjects involved in this study is displayed in Fig 1 and Table A in S1 Text. Latino cases and controls were derived from the California Cancer Records Linkage Project (CCRLP), a data linkage and sample bank resource described previously [11]. Case eligibility criteria included: [i] histologic diagnosis of glioma (ICDO-3 9380 to 9451) reported to the California Cancer Registry between 1988 and 2011, [ii] under 20 years of age at diagnosis; and [iii] no previous diagnosis of any other cancer by 2011 or age 19, whichever came last. Pilocytic astrocytoma, WHO Grade I (ICD-O3 code 9421) constituted about 1/3 of all identified glioma cases and forms the basis of the current report. Demographic data for all 2788 pediatric glioma cases meeting the eligibility criteria, with an archived newborn bloodspot (ANBS) available, and successfully genotyped are shown in Table A in S1 Text. Control eligibility criteria were similar to those for cases, based on the linkage between the California Cancer Registry (for absence of cancer) and California birth records. Controls were matched to cases (individually, based on month and year of birth, parental ethnicity, and sex) and randomly selected from the statewide birth records. Numbers of cases and controls included were shown in Fig 1. The State of California Committee for the Protection of Human Subjects (CPHS), as well as the University of Southern California and University of California, Berkeley institutional review boards approved this study. The CPHS IRB Project number is 15-05-2005.

Fig 1. Flowchart for data processing and analysis.

Fig 1

Open in a new tab

Genotyping

For each subject, a single 1.4 cm diameter ANBS was excised by the Biobank Program at the California Department of Public Health, labeled with study identifiers, and individually bagged. Batches of ANBS were shipped on ice packs to Dr. Wiemels’ Childhood Cancer Research Laboratory at University of Southern California. Then a 1/3 portion of the card was cut and processed. DNA was isolated with Agincourt chemistry on an Eppendorf robot, and quantified with pico-green. 500ng of genomic DNA was genotyped with the Precision Medicine Diversity Array, a Thermofisher Affymetrix product that assays > 900,000 SNPs genome-wide. Genotypes were called with Affymetrix Power Tools (APT), and resulting genotypes subjected to quality control procedures, including: call-rate filtering (samples and SNPs with more than 5% missing data were excluded), sex checks, cryptic relatedness filtering (IBD<0.25), and SNP filtering based on Hardy-Weinberg equilibrium (SNPs with P<10−4 among controls were removed). The less stringent HWE P-value cutoff was chosen (which more typically is 10−5, or -6 [12]) to incorporate SNPs that may deviate slightly due to recent admixture.

Estimation of ancestry proportions

To estimate the proportions of European, African and Amerindian ancestries in Latino case and control subjects, we used ADMIXTURE [13] with number of ancestries K = 3. The program was run 10 times and the average from each run was taken as the final estimate.

Reference subjects of European, Amerindian and African ancestries

A total of 3942 subjects with high quality SNP data passing gnomAD QC filters were selected from the Genome Aggregation Database (gnomAD) v3.1 [14], to be used as reference samples to estimate ancestral proportions for our CCRLP cases and controls. Among them, a total of 716 African reference subjects were selected based on self-reported ancestry, excluding African Caribbean in Barbados and African Ancestry in Southwest US as they are recently admixed populations. Reference subjects for European ancestry were also selected based on self-reported ancestry, excluding Finnish in Finland since they have population-specific bottleneck [15], and a total of 671 subjects were included. To select reference subjects of Amerindian ancestry, proportions of different ancestries were estimated with ADMIXTURE [13] (mean result of 10 runs), using number of ancestries (K = 5) determined by cross validation. A total of 94 subjects with >85% estimated Amerindian ancestry were selected to be the Amerindian reference population, of which 7 were Colombian, 12 were Karitianan, 14 were Mayan, 4 were of Mexican ancestry in Los Angeles, 37 were Peruvian in Lima, Peru, 12 were Pima and 8 were Suruí.

Inference of local ancestry and genome-wide association analysis

RFMix [16] was used to estimate local ancestry of Latino PA case and control subjects with default settings, using the reference panel described above. Genetic data of reference panel and query panel were phased and imputed with 1000 Genome Project as reference. Phasing and imputation were done using BEAGLE5 [17,18]. Genome-wide association analysis was then performed, regressing case-control status on number of European copies for each variant, controlling for potential confounding variables (sex, global European ancestry proportion, genetic principal components).

Statistical analysis

Genotyped SNP array data were first imputed and phased using BEAGLE5 [17,18]. Association between number of European copies and risk of pilocytic astrocytoma for each SNP in Latino subjects was then tested using logistic regression models adjusting for estimated global European ancestry proportion, sex and the first 10 genetic principal components. Genome-wide significance threshold for admixture mapping using test statistic simulation method was calculated using “STEAM”[19] package in R.

Association analyses for these SNPs around admixture mapping signals was conducted using logistic regression models for Latinos and non-Latino whites separately. Meta-analysis of these fine mapping results was performed using the METAL software package [20]. Number of independent SNPs were determined after pruning each region using PLINK2, in Europeans and Latinos separately. Average was taken for meta-analysis results, to be used in multiple corrections of association analysis results.

Results

European genomic ancestry is elevated in PA cases among Californian Latinos

Global ancestries of both Latino query panel (Latino pilocytic case and control subjects) and reference panel (reference subjects of European, African, and Amerindian ancestries) were partitioned into three components (European, African, Amerindian) using ADMIXTURE. As seen in Fig 2, Latino subjects possessed a similar mixture of European and Amerindian ancestry proportions and a small contribution from African ancestry. Subjects in the reference panels were also confirmed to predominantly come from the single ancestral group to which they were originally assigned.

Fig 2.

Fig 2

Open in a new tab

Estimated ancestry proportions for query Latino subjects and reference samples: Partition of global ancestries into three components: European ancestry (orange), African ancestry (blue) and Amerindian ancestry (red). Latino, CCRLP Latino pilocytic astrocytoma cases and controls; EUR, reference subjects of European ancestries; AFR, reference subjects of African ancestries; AMR, reference subjects of Amerindian ancestries.

Latino PA cases had a significantly higher proportion of European genomic ancestry compared to controls (Fig 3A) (case median = 55%, control median = 51%, Wilcoxon rank sum test P = 3.38x10-3). Each 5% increase in European ancestry proportion associated with a 1.051-fold increase in odds of PA among Latinos (95% CI: 1.014–1.091). Correspondingly, cases had a lower proportion of Amerindian ancestry (Fig 3B) (case median = 40%, control median = 43%, Wilcoxon rank sum test P = 1.36x10-3). No significant difference was observed for African ancestry (case median = 3.76%, control median = 3.93%, Wilcoxon rank sum test P = 0.221). Essentially identical results were calculated when RFMix output was used instead of ADMIXTURE for ancestry calculations.

Fig 3.

Fig 3

Open in a new tab

Distribution of ancestry proportions in Latino pilocytic and non-pilocytic astrocytoma cases and controls: 3A. boxplot showing distribution of estimated global European ancestry proportion in Latino pilocytic case and control subjects. Cases have a higher median proportion of European ancestry proportion than controls. 3B. boxplot showing distribution of estimated global Amerindian ancestry proportions, and in correspondence with 3A, cases have a lower median proportion of Amerindian ancestry proportion than controls. 3C. a boxplot showing distribution of estimated global European ancestry proportion in Latino non-pilocytic case and control subjects. Comparing to pilocytic astrocytoma, cases have a similar median proportion of European ancestry proportion to controls. Statistical analysis shows no significant difference between cases and controls.

Central Brain Tumor of the United States data revealed that unlike pilocytic astrocytoma, other subtypes of pediatric astrocytoma do not display a disproportionately higher incidence rate in populations of European descent compared to other ancestral groups [8]. To observe whether global ancestry comparisons support these registry-based assessments, we compared the proportions of European ancestry in Latino non-PA (n = 1076, Table B in S1 Text) cases and controls, observing no significant differences in ancestry (Wilcoxon rank sum test P = 0.219) (Fig 3C).

Admixture Mapping in Latino PA cases and controls

Admixture mapping was performed in Latino PA cases and controls using RFMix, followed by a genome-wide association analysis between number of European copies for each SNP and PA status, controlling for estimated global European ancestry, sex and first 10 genetic principal components (Fig 4A) [21]. Genome-wide significance level was determined by STEAM [19] to be 7.75 x 10−6 as shown in Fig 4A. One region of 13 linked SNPs in SNX14 on 6q14.3 surpassed the threshold for genome-wide statistical significance (Fig 4B). One additional copy of the European ancestral haplotype at the most significant site was associated with 1.59-fold increased odds of PA (smallest P-value from admixture mapping at chr6:85504599; P = 4.70x10-6). Additional peaks approaching, but not reaching, genome-wide significance were identified on chromosomes 7 (Fig 4C), 10 (Fig 4D) and 13 (Fig 4E).

Fig 4. Association plots local European ancestry copies and risk of pilocytic astrocytoma in Latino subjects: 4A.

Fig 4

Open in a new tab

An association plot of local European ancestry and pilocytic astrocytoma risk (admixture mapping) in Latino subjects, controlling for global European ancestry proportion, sex and first 10 genetic principal components. Significance level was determined by “STEAM” package to be 7.75x10-06, and estimated number of generations for this group is 12.2. 4B. Zoomed in peak of 4A for Chromosome 6 peak. 4C. Zoomed in peak of 4A for Chromosome 7 peak. 4D. Zoomed in peak of 4A for Chromosome 10 peak. 4E. Zoomed in peak of 4A for Chromosome 13 peak.

Fine mapping of the regional admixture mapping peak

Based on the widths of admixture peaks, we performed association analysis in the regions of admixture mapping signals to identify individual SNPs potentially associated with PA risk. Association analyses in the 3MB region surrounding the chr6 peak (chr6: 84009612–87009612) were performed in CCRLP Latinos (Fig 5A1) and non-Latino White cohorts (Fig 5A2) separately using logistic regression models adjusting for sex and PCs, then meta-analyzed (Fig 5A3). Bonferroni correction was performed based on the number of independent SNPs (n = 2,352 in Latinos, n = 2,394 in Europeans, n = 2,373 for meta-analysis). No SNPs reached significance after multiple-test correction, however several lead SNPs from the meta-analysis were identified, including rs191186144 (P value = 1.64x10-3, intronic region of MRAP2), rs74559531 (P value = 2.22x10-3, intronic region of HTR1E), and rs4707205 (P value = 4.05x10-3, upstream region of NT5E). All are located in brain-expressed genes that play biological roles in brain development/function or cancer development (Table 1).

Fig 5. Case-control association analyses between SNPs and pilocytic astrocytoma risk of CCRLP Latino, European subjects and meta-analysis of both results in regions of admixture mapping peaks A1, fine mapping of the 3 Mb region of chromosome 6 admixture mapping peak in CCRLP Latino subjects.

Fig 5

Open in a new tab

A2, fine mapping of the 3 Mb region of chromosome 6 admixture mapping peak in CCRLP European subjects. A3, meta-analysis of results from A1 and A2. B1, fine mapping of the 2 Mb region of chromosome 7 admixture mapping peak in CCRLP Latino subjects. B2, fine mapping of the 2 Mb region of chromosome 7 admixture mapping peak in CCRLP European subjects. B3, meta-analysis of results from B1 and B2. C1, fine mapping of the 2 Mb region of chromosome 10 admixture mapping peak in CCRLP Latino subjects. C2, fine mapping of the 2 Mb region of chromosome 10 admixture mapping peak in CCRLP European subjects. C3, meta-analysis of results from C1 and C2. D1, fine mapping of the 2 Mb region of chromosome 13 admixture mapping peak in CCRLP Latino subjects. D2, fine mapping of the 2 Mb region of chromosome 13 admixture mapping peak in CCRLP European subjects. D3, meta-analysis of results from D1 and D2.

Table 1. Top SNPs from fine mapping analyses of admixture mapping peaks.

Locus Nearest Gene(s) SNP Position (bp, hg38) Risk Allele Dataset Risk Allele Freq OR SE P-value
6q14.2 MRAP2 rs191186144 84,058,087 A CCRLP Lat 0.013 1.533 0.346 0.217
CCRLP Eur 0.029 1.780 0.197 3.478x10-3
Meta-analysis 1.716 0.171 1.637x10-3
6q14.3 HTR1E rs74559531 86,961,711 A CCRLP Lat 0.010 0.573 0.547 0.309
CCRLP Eur 0.025 2.204 0.214 2.285x10-4
Meta-analysis 1.842 0.200 2.221x10-3
6q14.3 NT5E rs4707205 854,39,850 C CCRLP Lat 0.033 1.644 0.230 3.044x10-2
CCRLP Eur 0.059 1.387 0.165 4.714x10-2
Meta-analysis 1.469 0.134 4.049x10-3
7q14.3 NEUROD6 rs113651799 31,316,499 G CCRLP Lat 0.025 1.613 0.256 0.061
CCRLP Eur 0.028 1.641 0.204 0.016
Meta-analysis 1.630 0.160 2.215x10-3
7q14.3 NEUROD6 rs17473169 31,324,183 A CCRLP Lat 0.057 1.476 0.182 0.0321
CCRLP Eur 0.077 1.324 0.131 0.0322
Meta-analysis 1.374 0.106 2.788 x10-3
7q14.3 MTURN rs34393279 30,138,553 G CCRLP Lat 0.163 1.770 0.234 0.0146
CCRLP Eur 0.242 1.405 0.180 0.0588
Meta-analysis 1.531 0.143 2.824x10-3
10p12.1 LYZL1 rs959431 29,099,450 C CCRLP Lat 0.116 1.547 0.139 1.701x10-3
CCRLP Eur 0.150 1.214 0.101 0.0547
Meta-analysis 1.320 0.0818 6.764x10-4
10p12.1 LYZL1 rs555108 29,090,828 T CCRLP Lat 0.080 1.552 0.158 5.403x10-3
CCRLP Eur 0.118 1.272 0.110 0.0289
Meta-analysis 1.358 0.0904 7.148x10-4
10p12.1 LYZL1 rs550240 29,094,615 A CCRLP Lat 0.080 1.548 0.158 5.67x10-3
CCRLP Eur 0.118 1.271 0.110 0.0294
Meta-analysis 1.356 0.0904 7.531x10-4
13q31.3 GPC6 rs9584173 93,952,876 G CCRLP Lat 0.262 0.681 0.121 1.534x10-3
CCRLP Eur 0.157 0.819 0.110 0.0693
Meta-analysis 0.754 0.0814 5.112x10-4
13q32.1 ABCC4 rs146402029 95,250,755 T CCRLP Lat 0.036 0.882 0.487 0.797
CCRLP Eur 0.065 2.620 0.244 8.113x10-5
Meta-analysis 2.105 0.219 6.540x10-4
13q31.3 GPC6 rs1264672115 93,930,275 G CCRLP Lat 0.277 0.708 0.117 3.251x10-3
CCRLP Eur 0.166 0.815 0.106 0.0537
Meta-analysis 0.765 0.0787 6.608x10-4
Open in a new tab

Similarly, we also investigated 2Mb regions around the admixture mapping peaks on chromosomes 7, 10 and 13 that approached genome-wide significance (Fig 5B for chromosome 7, Fig 5C for chromosome 10, and Fig 5D for chromosome 13). No SNPs reached significance after multiple-test correction, and we report the 3 lead SNPs from each analysis in Table 1.

Conditional analysis on regional admixture mapping signatures

We conducted conditional analyses in regions of admixture mapping peaks to identify potential SNPs that could account for the signals. For each region, we added the top 3 SNPs from meta-analysis into the admixture mapping regression model, one by one, and observed if the association signal was eliminated. There were slight decreases in signal significance for peaks on chromosomes 6 and 13, and the adjusted effect sizes were also closer to null (Table C in S1 Text). However, the degree of changes were all marginal, suggesting locus-specific admixture signals contribute to these associations but are not well-explained by case-control differences in allele frequencies at the models SNPs.

Discussion

In this large, population-based case-control study of pediatric PA and matched healthy controls in California, we observe a strong association between elevated European genomic ancestry and PA risk in our Latino study subjects. Specifically, every 5% increase in European ancestry proportion was associated with a 1.051-fold increase in odds of contracting PA among Latinos. Because cases were identified from a statewide registry data linkage dataset with careful matching of population-based controls, these results indicate that genomic ancestry contributes to PA risk, likely due to differing frequencies of underlying risk alleles across racial/ethnic groups. Additional etiologic factors such as potential environmental risk factors were not assessed in our study, but merit assessment in future research.

Additional glioma subtypes have also been reported to occur more frequently in non-Latino whites than other racial/ethnic groups, including childhood ependymoma [22], adult glioblastoma and oligodendroglioma [23]. Global ancestry analysis has previously revealed that childhood ependymoma risk is associated with higher European ancestry in U.S. Latinos [9], but we did not observe ancestral differences among any other subtypes of astrocytoma in this study aside from PA. Therefore, cases of both pilocytic astrocytoma and non-pilocytic astrocytoma showed a consistency between epidemiologic incidence and global ancestry distribution, consistent with the hypothesis that genetic risk captures a proportion of the incidence disparity for pediatric pilocytic astrocytoma.

The observation that the European ancestral proportion was associated with elevated PA risk in our study implicates a higher frequency of PA risk alleles on European haplotypes and led us to perform local admixture mapping analyses. Admixture mapping and subsequent fine-mapping using traditional allelic association testing in a logistic regression framework identified an admixture peak at 6q14.3 region (a 34,268 bp region, chr6:85,502,415–85,536,682). This region contains the SNX14 gene, which codes a protein in the sorting nexin family involved in the sorting of endosomes. SNX14 maintains microtubule organization and axonal transport in neurons and glia [24], is thereby critical to maintenance of Purkinje cells [25], and has been shown to regulate neuronal intrinsic excitability and synaptic transmission in mice [24]. Its loss is associated Spinocerebellar Ataxia (SCAR20) and Vici Syndrome, rare childhood-onset neurodevelopmental diseases [26,27]. One possible mechanism for the risk allele in SNX14 to increase PA risk is through promoting tumorigenic microenvironment. It was reported that synaptic activity was involved in shedding neuroligin 3 (NLGN3), which was required in the process of PA gliomagenesis [28].

We also carried out genotypic association analyses in this identified region in both European and Latino PA subjects. No SNP reached significance after Bonferroni correction, likely due to a lack of power. However, we identified potential alleles that could contribute to PA risk in these regions. For example, NT5E is associated with HIF-1-α transcription factor network, and many genes induced by HIF-1-α are highly expressed in cancer, including angiogenic growth factors (VEGF for example) and glucose metabolism enzymes [29]. It was also the most significant SNP in chromosome 6 fine-mapping results. Furthermore, RNA-seq profiles were recently used to conduct pseudotime analysis of PA cell development, demonstrating a cellular trajectory of PA progress [30]. Cells with low pseudotime were reported to have high MAPK signaling score and highly expressed MAPK genes comparing to cells with high pseudotime [30]. Interestingly, almost all our top genes in the association analysis were involved in the MAPK pathway. For example, the MAPK signaling gene program identified by Reitman et al [30] included CCDC144B, and LYZL1 (rs959431, rs555108, rs550240), one of the top genes we identified, is also reported by STRING [31] to interact with multiple members of the CCDC family including CCDC42 and CCDC73. The activation of HTR1E (rs74559531) has been reported to stimulate the MAPK/ERK signaling cascade [32]. NT5E (rs4707205) was shown to be a direct binder of miR-193b, an miRNA involved in the MAPK pathway [33]. NEUROD6 (rs113651799, rs17473169) was also shown in mouse CRE models to be associated with phosphorylation of ERK/MAPK substrates [34]. MTURN (rs34393279) was reported to positively regulate MAPK/ERK pathway [35]. GPC6 (rs9584173, rs1264672115) could promote non-canonical Wnt5A pathway leading to the activation of p38 MAPK [36]. Finally, ABCC4 (rs146402029) was thought to regulate intracellular and extracellular cAMP levels [37], and cAMP was demonstrated to inhibit MAPK [38]. While activation of MAPK/ERK signal transduction, a central mitogenic cell growth pathway, by somatic mutation of BRAF is well recognized in pilocytic astrocytoma [2], the associations shown here suggest that activation by germline genetic variation of MAPK/ERK signal transduction may also contribute to the higher risk of this disease carried by European ancestry.

While the presence of one and up to three regions were identified in this admixture analysis, we acknowledge the lack of a replication in an independent dataset as a weakness to the current study. We would therefore encourage replication in future cohorts of pilocytic tumors particularly those derived from EUR populations. Another limitation of our study is lack of environmental covariates that could contribute to differences in PA risks in different racial/ethnic groups. While this would not affect our global ancestry comparisons due to the registry-based approach to case-identification and control selection, lack of environment covariates precludes examination of potentially important gene-environment interactions. Another limitation was that we had a comparatively smaller number of subjects in the Amerindian reference panel. This could potentially affect regional admixture accuracy and bias results toward the null.

In conclusion, we observed that a higher proportion of European ancestry was associated with increased risk of childhood PA, with admixture mapping and subsequent association analysis identifying a region of 6q14.3 potentially contributing to this risk.

Supporting information

S1 Text. Table A in S1 Text, Demographic data of pediatric astrocytoma subjects; Table B in S1 Text: Description of Latino non-pilocytic astrocytoma cases and controls; Table C in S1 Text, conditional analysis in admixture mapping peaks.

(DOCX)

Click here for additional data file. (21.5KB, docx)

Data Availability

Our data is derived from the California Biobank. We respectfully are unable to share raw, individual genetic data freely with other investigators since the samples and the data are the property of the State of California. Should we be contacted by other investigators who would like to use the data, we will direct them to the California Department of Public Health Institutional Review Board to establish their own approved protocol to utilize the data, which can then be shared peer-to-peer. The State has provided guidance on data sharing noted in the statement below: "California has determined that researchers requesting the use of California Biobank biospecimens for their studies will need to seek an exemption from NIH or other granting or funder requirements regarding the uploading of study results into an external bank or repository (including into the NIH dbGaP or other bank or repository). This applies to any uploading of genomic data and/or sharing of these biospecimens or individual data derived from these biospecimens. Such activities have been determined to violate the statutory scheme at California Health and Safety Code Section 124980 (j), 124991 (b), (g), (h) and 103850 (a) and (d), which protect the confidential nature of biospecimens and individual data derived from biospecimens. Investigators may agree to share aggregate data on SNP frequency and their associated p-values with other investigators and may upload such frequencies into repositories including the NIH dbGaP repository providing: a) the denominator from which the data is derived includes no fewer than 20,000 individuals; b) no cell count is for < 5 individuals; and c) no correlations or linkage probabilities between SNPs are provided.) Since our dataset is derived from less than 20,000 subjects, we are not able to upload the data to dbGAP or another repository. All underlying numerical data used to create figures are available at https://doi.org/10.7910/DVN/FFBYRT.

Funding Statement

This study is funded by The National Cancer Institute (NCI) of National Institutes of Health (NIH) R01CA194189 to JLW and KMW. Website: https://www.cancer.gov The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Bornhorst M, Frappaz D, Packer RJ. Pilocytic astrocytomas. Handbook of Clinical Neurology. Elsevier; 2016. pp. 329–344. doi: [DOI] [PubMed] [Google Scholar]
  • 2.Collins VP, Jones DTW, Giannini C. Pilocytic astrocytoma: pathology, molecular mechanisms and markers. Acta Neuropathol (Berl). 2015;129: 775–788. doi: 10.1007/s00401-015-1410-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Gutmann DH, McLellan MD, Hussain I, Wallis JW, Fulton LL, Fulton RS, et al. Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res. 2013;23: 431–439. doi: 10.1101/gr.142604.112 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Janzarik W, Kratz C, Loges N, Olbrich H, Klein C, Schäfer T, et al. Further Evidence for a Somatic KRAS Mutation in a Pilocytic Astrocytoma. Neuropediatrics. 2007;38: 61–63. doi: 10.1055/s-2007-984451 [DOI] [PubMed] [Google Scholar]
  • 5.Duerr E-M, Rollbrocker B, Hayashi Y, Peters N, Meyer-Puttlitz B, Louis DN, et al. PTEN mutations in gliomas and glioneuronal tumors. Oncogene. 1998;16: 2259–2264. doi: 10.1038/sj.onc.1201756 [DOI] [PubMed] [Google Scholar]
  • 6.Andrews LJ, Thornton ZA, Saincher SS, Yao IY, Dawson S, McGuinness LA, et al. Prevalence of BRAFV600 in glioma and use of BRAF Inhibitors in patients with BRAFV600 mutation-positive glioma: systematic review. Neuro-Oncol. 2021; noab247. doi: 10.1093/neuonc/noab247 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Helfferich J, Nijmeijer R, Brouwer OF, Boon M, Fock A, Hoving EW, et al. Neurofibromatosis type 1 associated low grade gliomas: A comparison with sporadic low grade gliomas. Crit Rev Oncol Hematol. 2016;104: 30–41. doi: 10.1016/j.critrevonc.2016.05.008 [DOI] [PubMed] [Google Scholar]
  • 8.Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncol. 2020;22: iv1–iv96. doi: 10.1093/neuonc/noaa200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Zhang C, Ostrom QT, Hansen HM, Gonzalez-Maya J, Hu D, Ziv E, et al. European genetic ancestry associated with risk of childhood ependymoma. Neuro-Oncol. 2020;22: 1637–1646. doi: 10.1093/neuonc/noaa130 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ostrom QT, Egan KM, Nabors LB, Gerke T, Thompson RC, Olson JJ, et al. Glioma risk associated with extent of estimated European genetic ancestry in African Americans and Hispanics. Int J Cancer. 2020;146: 739–748. doi: 10.1002/ijc.32318 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Wiemels JL, Walsh KM, de Smith AJ, Metayer C, Gonseth S, Hansen HM, et al. GWAS in childhood acute lymphoblastic leukemia reveals novel genetic associations at chromosomes 17q12 and 8q24.21. Nat Commun. 2018;9: 286. doi: 10.1038/s41467-017-02596-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Coleman JRI, Euesden J, Patel H, Folarin AA, Newhouse S, Breen G. Quality control, imputation and analysis of genome-wide genotyping data from the Illumina HumanCoreExome microarray. Brief Funct Genomics. 2016;15: 298–304. doi: 10.1093/bfgp/elv037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Alexander DH, Novembre J, Lange K. Fast model-based estimation of ancestry in unrelated individuals. Genome Res. 2009;19: 1655–1664. doi: 10.1101/gr.094052.109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581: 434–443. doi: 10.1038/s41586-020-2308-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Wang SR, Agarwala V, Flannick J, Chiang CWK, Altshuler D, Hirschhorn JN, et al. Simulation of Finnish Population History, Guided by Empirical Genetic Data, to Assess Power of Rare-Variant Tests in Finland. Am J Hum Genet. 2014;94: 710–720. doi: 10.1016/j.ajhg.2014.03.019 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Maples BK, Gravel S, Kenny EE, Bustamante CD. RFMix: a discriminative modeling approach for rapid and robust local-ancestry inference. Am J Hum Genet. 2013;93: 278–288. doi: 10.1016/j.ajhg.2013.06.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Browning BL, Zhou Y, Browning SR. A One-Penny Imputed Genome from Next-Generation Reference Panels. Am J Hum Genet. 2018;103: 338–348. doi: 10.1016/j.ajhg.2018.07.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Browning BL, Tian X, Zhou Y, Browning SR. Fast two-stage phasing of large-scale sequence data. Am J Hum Genet. 2021;108: 1880–1890. doi: 10.1016/j.ajhg.2021.08.005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Grinde KE, Brown LA, Reiner AP, Thornton TA, Browning SR. Genome-wide Significance Thresholds for Admixture Mapping Studies. Am J Hum Genet. 2019;104: 454–465. doi: 10.1016/j.ajhg.2019.01.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26: 2190–2191. doi: 10.1093/bioinformatics/btq340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation PLINK: rising to the challenge of larger and richer datasets. GigaScience. 2015;4: 7. doi: 10.1186/s13742-015-0047-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Leece R, Xu J, Ostrom QT, Chen Y, Kruchko C, Barnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro-Oncol. 2017;19: 1553–1564. doi: 10.1093/neuonc/nox091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ostrom QT, Cote DJ, Ascha M, Kruchko C, Barnholtz-Sloan JS. Adult Glioma Incidence and Survival by Race or Ethnicity in the United States From 2000 to 2014. JAMA Oncol. 2018;4: 1254. doi: 10.1001/jamaoncol.2018.1789 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Zhang H, Hong Y, Yang W, Wang R, Yao T, Wang J, et al. SNX14 deficiency-induced defective axonal mitochondrial transport in Purkinje cells underlies cerebellar ataxia and can be reversed by valproate. Natl Sci Rev. 2021;8: nwab024. doi: 10.1093/nsr/nwab024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Akizu N, Cantagrel V, Zaki MS, Al-Gazali L, Wang X, Rosti RO, et al. Biallelic mutations in SNX14 cause a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Nat Genet. 2015;47: 528–534. doi: 10.1038/ng.3256 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Byrne S, Dionisi-Vici C, Smith L, Gautel M, Jungbluth H. Vici syndrome: a review. Orphanet J Rare Dis. 2016;11: 21. doi: 10.1186/s13023-016-0399-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Bird TD. Hereditary Ataxia Overview. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Mirzaa G, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993. Available: http://www.ncbi.nlm.nih.gov/books/NBK1138/ [PubMed] [Google Scholar]
  • 28.Pan Y, Hysinger JD, Barron T, Schindler NF, Cobb O, Guo X, et al. NF1 mutation drives neuronal activity-dependent initiation of optic glioma. Nature. 2021;594: 277–282. doi: 10.1038/s41586-021-03580-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Weidemann A, Johnson RS. Biology of HIF-1α. Cell Death Differ. 2008;15: 621–627. doi: 10.1038/cdd.2008.12 [DOI] [PubMed] [Google Scholar]
  • 30.Reitman ZJ, Paolella BR, Bergthold G, Pelton K, Becker S, Jones R, et al. Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. Nat Commun. 2019;10: 3731. doi: 10.1038/s41467-019-11493-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43: D447–452. doi: 10.1093/nar/gku1003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Sun C, Qiu Y, Ren Q, Zhang X, Cao B, Zou Y, et al. Molecular Cloning and Functional Characterization of Three 5-HT Receptor Genes (HTR1B, HTR1E, and HTR1F) in Chickens. Genes. 2021;12: 891. doi: 10.3390/genes12060891 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Kordaß T, Osen W, Eichmüller SB. Controlling the Immune Suppressor: Transcription Factors and MicroRNAs Regulating CD73/NT5E. Front Immunol. 2018;9: 813. doi: 10.3389/fimmu.2018.00813 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Xing L, Larsen RS, Bjorklund GR, Li X, Wu Y, Philpot BD, et al. Layer specific and general requirements for ERK/MAPK signaling in the developing neocortex. eLife. 2016;5: e11123. doi: 10.7554/eLife.11123 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Sun X, Lu B, Hu B, Xiao W, Li W, Huang Z. Novel function of the chromosome 7 open reading frame 41 gene to promote leukemic megakaryocyte differentiation by modulating TPA-induced signaling. Blood Cancer J. 2014;4: e198–e198. doi: 10.1038/bcj.2014.18 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Yiu GK, Kaunisto A, Chin YR, Toker A. NFAT promotes carcinoma invasive migration through glypican-6. Biochem J. 2011;440: 157–166. doi: 10.1042/BJ20110530 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Carozzo A, Diez F, Gomez N, Cabrera M, Shayo C, Davio C, et al. Dual Role of cAMP in the Transcriptional Regulation of Multidrug Resistance-Associated Protein 4 (MRP4) in Pancreatic Adenocarcinoma Cell Lines. Berdeaux R, editor. PLOS ONE. 2015;10: e0120651. doi: 10.1371/journal.pone.0120651 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Schmidt CM, McKillop IH, Cahill PA, Sitzmann JV. The role of cAMP-MAPK signalling in the regulation of human hepatocellular carcinoma growth in vitro. Eur J Gastroenterol Hepatol. 1999;11: 1393–1399. doi: 10.1097/00042737-199912000-00009 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Peter McKinnon, Zoltán Kutalik

12 Jul 2022

Dear Dr Wiemels,

Thank you very much for submitting your Research Article entitled 'Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children' to PLOS Genetics.

The manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some concerns that we ask you address in a revised manuscript

We therefore ask you to modify the manuscript according to the review recommendations. Your revisions should address the specific points made by each reviewer.

In addition we ask that you:

1) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our archive. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Zoltán Kutalik, PhD

Associate Editor

PLOS Genetics

Peter McKinnon

Section Editor: Cancer Genetics

PLOS Genetics

Summary: As the authors can observe, the reviewers commented favourably on the manuscript, but raised some technical questions and required additional clarifications. In particular, the authors are welcome to perform a case-only analysis to potentially boost power (while the assumptions need to be explored). Also, either the authors should justify the use of ADMIXTURE over RFMix, or as a sensitivity analysis, try RFMix to compare the results for global ancestry.

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: See attachment

Reviewer #2: Pilocytic astrocytoma (PA) is the most common pediatric brain tumor, but a rare phenotype, with an average annual age-adjusted incidence rate ranging from 0.13-0.38 per 100,000 per year in various population groups. PA incidence is increased in European populations.

The manuscript entitled “Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children” by Li et al reports an admixture mapping study of 301 P) cases, 1185 population controls and 246 non-pilocytic astrocytoma cases. These samples were genotyped using the Precision Medicine Diversity Array (Thermofisher) which interrogates more than 900 000 SNPs genome-wide. The resulting dataset was analysed together with reference population data and global and local ancestry were inferred to facilitate admixture mapping. Samples from 1569 European controls and 471 European PA cases were also available for fine-mapping.

Global European ancestry was associated with PA and admixture mapping identified variants on chromosome 6 in the SNX14 gene that contribute to risk. Three other chromosomal locations were not significant associated with risk, but were suggestive of assocations. Fine mapping in these regions identified additional variants related to the MAPK pathway that affect the risk of childhood PA.

The data analyses were performed with technical rigor. The figures and tables support the findings presented in the manuscript.

Major Comments:

1. The current gold standard program to infer global ancestry is RFMix. Please justify the use of ADMIXTURE, since RFMix was used to infer local ancestry.

2. After merging with the reference population, what was the SNP density?

Minor comments:

3. Although I am sure the appropriate IRB approvals were obtained from the California Department of Public Health Institutional Review Board, none of the approval numbers are listed in the manuscript.

4. Please show the individual values of the ancestry proportions in the box plots in Figure 3.

5. Please remove references to “race” in the manuscript. To quote, “Race is a social construct” as indicated by the American Society of Human Genetics. (https://www.cell.com/ajhg/fulltext/S0002-9297(18)30363-X ) Rather use ethnicity or ancestry, as you have done throughout most of the text.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: No: The authors state that the data belongs to the State of California and a separate protocol application will be needed.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Attachment

Submitted filename: Review of Li et al_2022.docx

Click here for additional data file. (15.2KB, docx)

Decision Letter 1

Peter McKinnon, Zoltán Kutalik

21 Aug 2022

Dear Dr Wiemels,

We are pleased to inform you that your manuscript entitled "Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please also consider the remaining concern raised by reviewer #1. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional acceptance, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about making your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Zoltán Kutalik, PhD

Academic Editor

PLOS Genetics

Peter McKinnon

Section Editor

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

The reviewers appreciated the thorough revision and the paper is now acceptable for publication. We leave it up to the authors to decide whether they take into account the (we believe valid) comment from Reviewer #1 about the crucially different meaning of the HWE filter in such admixed setting.

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: While I am happy with the revision, I still have a comment about the HWE cutoff

Page 7 bottom. Regarding removal of SNPs on the basis of HWE: Incomplete admixture causes failures of HWE, but this is not a bad thing, it just reflects the underlying genetic architecture. The point of testing for HWE is to aid in the search for SNPs affected by genotyping error, not to eliminate well-genotyped SNPs that happen to have different allele frequencies in the ancestral populations. Those SNPs are the most influential for admixture mapping. I would therefore advocate tightening the p-values used to remove SNPs on the basis of HWE (making the p-value smaller). I doubt this would make much difference in the analysis but what is written on page 7 strikes me as odd.

Also, on page 10 second paragraph. What is the meaning of the term “query Latino subjects”?

Reviewer #3: The authors have responded efficiently to all comments and I have nothing further to add.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: None

Reviewer #3: No: Californian Biobank data - no individual level, raw data is available.

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #3: No

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: 

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-22-00506R1

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

Peter McKinnon, Zoltán Kutalik

2 Sep 2022

PGENETICS-D-22-00506R1

Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children

Dear Dr Wiemels,

We are pleased to inform you that your manuscript entitled "Localized variation in ancestral admixture identifies pilocytic astrocytoma risk loci among Latino children" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Zsofi Zombor

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Text. Table A in S1 Text, Demographic data of pediatric astrocytoma subjects; Table B in S1 Text: Description of Latino non-pilocytic astrocytoma cases and controls; Table C in S1 Text, conditional analysis in admixture mapping peaks.

    (DOCX)

    Click here for additional data file. (21.5KB, docx)
    Attachment

    Submitted filename: Review of Li et al_2022.docx

    Click here for additional data file. (15.2KB, docx)
    Attachment

    Submitted filename: admixture_mapping_response.docx

    Click here for additional data file. (195.3KB, docx)

    Data Availability Statement

    Our data is derived from the California Biobank. We respectfully are unable to share raw, individual genetic data freely with other investigators since the samples and the data are the property of the State of California. Should we be contacted by other investigators who would like to use the data, we will direct them to the California Department of Public Health Institutional Review Board to establish their own approved protocol to utilize the data, which can then be shared peer-to-peer. The State has provided guidance on data sharing noted in the statement below: "California has determined that researchers requesting the use of California Biobank biospecimens for their studies will need to seek an exemption from NIH or other granting or funder requirements regarding the uploading of study results into an external bank or repository (including into the NIH dbGaP or other bank or repository). This applies to any uploading of genomic data and/or sharing of these biospecimens or individual data derived from these biospecimens. Such activities have been determined to violate the statutory scheme at California Health and Safety Code Section 124980 (j), 124991 (b), (g), (h) and 103850 (a) and (d), which protect the confidential nature of biospecimens and individual data derived from biospecimens. Investigators may agree to share aggregate data on SNP frequency and their associated p-values with other investigators and may upload such frequencies into repositories including the NIH dbGaP repository providing: a) the denominator from which the data is derived includes no fewer than 20,000 individuals; b) no cell count is for < 5 individuals; and c) no correlations or linkage probabilities between SNPs are provided.) Since our dataset is derived from less than 20,000 subjects, we are not able to upload the data to dbGAP or another repository. All underlying numerical data used to create figures are available at https://doi.org/10.7910/DVN/FFBYRT.

    Articles from PLoS Genetics are provided here courtesy of PLOS

    RESOURCES